Celgosivir hydrochloride is under clinical development by 60 Degrees Pharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Celgosivir hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Celgosivir hydrochloride overview

Celgosivir hydrochloride is under development for the treatment of respiratory syncytial virus (RSV) infections, and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through the oral route. Celgosivir (6-O-butanoyl castanospermine) is a pro-drug of the naturally occurring castanospermine. It acts by targeting alpha-glucosidase I. It was under development for the treatment of zika virus infections, dengue fever and other viral infections.

60 Degrees Pharmaceuticals overview

60 Degrees Pharmaceuticals LLC (60 Degrees) is a biopharmaceutical company that discovers, develops and markets medicines for the treatment and prevention of tropical diseases. It also provides drug research and development services. 60 Degrees is headquartered in Washington DC, the US.

For a complete picture of Celgosivir hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.